[20190612]IF10219_阿片类药物治疗方案和相关联邦法规.pdf

上传人:任我行 文档编号:28278 上传时间:2022-06-24 发布时间:2019-06-12 格式:PDF 页数:3 大小:422.90KB
下载 相关 举报
[20190612]IF10219_阿片类药物治疗方案和相关联邦法规.pdf_第1页
第1页 / 共3页
[20190612]IF10219_阿片类药物治疗方案和相关联邦法规.pdf_第2页
第2页 / 共3页
[20190612]IF10219_阿片类药物治疗方案和相关联邦法规.pdf_第3页
第3页 / 共3页
亲,该文档总共3页,全部预览完了,如果喜欢就下载吧!
资源描述

1、 https:/crsreports.congress.gov Updated June 12, 2019Opioid Treatment Programs and Related Federal RegulationsThe use of opioid medications to treat opioid addiction is subject to federal regulations beyond those that apply to the same medications used for other purposes (e.g., treating pain). The m

2、edications methadone and buprenorphine are both opioids; their use to treat opioid addiction is often called opioid substitution therapy, opioid replacement therapy, or opioid agonist treatment. Federally certified opioid treatment programs (OTPs)often called methadone clinicsoffer these opioid medi

3、cations in addition to counseling and other services for individuals addicted to heroin or other opioids. With few exceptions, the use of methadone to treat opioid addiction is limited to OTPs; however, physicians who wish to treat opioid addiction using buprenorphine may obtain a waiver to do so ou

4、tside an OTP. A non-opioid medication used in the treatment of opioid addiction, naltrexone, may be used by OTPs, physicians with waivers, or anyone with the authority to write prescriptions. To understand how OTPs are regulated, it is helpful to have some background information about the medication

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告